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Table 1
Patient Characteristics
Total Caphosol Cryotherapy Saline
Solution
p-value
Patients, n 117 39 40 38
Age, median
(range)
62
(39-75)
62
(45-68)
62
(39-75)
61.5
(43-70)
0.7696
Gender, n (%) 0.8962
Male 110 (94) 36 (92) 38 (95) 36 (95)
Female 7 (6) 3 (8) 2 (5) 2 (5)
Race/Ethnicity,
n (%)
0.5164
Caucasian 56 (48) 23 (59) 16 (40) 17 (45)
African
Americans
40 (34) 11 (28) 15 (37) 14 (37)
Hispanic 21 (18) 5 (13) 9 (23) 7 (18)
Karnofsky
score, n (%)
0.8394
70 1 (1) 0 (0) 1 (2.5) 0 (0)
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210S204Conclusion: Our institution experience with oral tacrolimus
for GVHD prophylaxis supports continuation of this practice
as a viable alternative to IV tacrolimus and results in signif-
icant cost savings.
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Background: Palifermin is a human recombinant keratino-
cyte growth factor. It was approved by the FDA in 2004
for decreasing the incidence and duration of oral mucositis
in patients receiving high dose chemotherapy and stem
cell rescue. Approval followed two randomized, placebo-
controlled, multicenter trials conducted in patients with
hematologic malignancies undergoing myeloablative condi-
tioningwith TBI. After approval, palifermin usewas extended
to non-TBI based conditioning regimens. In 2008, our insti-
tution began use of palifermin in lymphoma patients un-
dergoing BEAM conditioning and ASCT. Our goal in this study
was to assess the efﬁcacy of such a strategy in a non-TBI
based transplant group.
Methods: From 1/2008 through 6/2013 we performed 75
BEAM/ASCT on lymphoma patients using palifermin. We
compared this group to the preceding 75 lymphoma patients
who received BEAM auto-conditioning without it. The two
cohorts were compared for incidence of fever, positive blood
cultures, positive urine cultures, TPNuse, PCA use, and length
of stay (LOS). Data was collected retrospectively.
Results: Results are summarized in the table below. Of note,
there was a statistically signiﬁcant difference (p<0.05) of
fewer febrile episodes in the palifermin group and TPN use.
However there were no statistically signiﬁcant differences in
positive blood cultures, urine cultures, PCA use, or LOS.
Conclusion: Mucositis has been associated with increased
incidenceof fever. Inﬂammation rather than infectionhasbeen
postulated as themechanism formucosotis fever. Signiﬁcantly
fewer patients developed fevers in the palifermin group
though there was no difference in the incidence of positive
cultures. Palifermin reduced the use of fever workups and the
empiric use of antibiotics. TPN use was also curtailed by pal-
ifermin administration. Despite its mechanism of action of
decreasing mucositis, neither PCA use nor LOS differed sub-
stantially between the groups. It may be thatmucositis is not a
major rate-limiting step to discharge as symptoms often tend
to resolve shortly after engraftment. Further analysis
comparing time to engraftment with length of stay may helpTable
Comparison of Patient Arms (Palifermin vs. No Palifermin)
Characteristic Palifermin
(N¼75)
No Palifermin
(N¼75)
P-value
Fever 46 72 <0.05
Positive Blood Cultures 5 11 NS
Positive Urine Cultures 11 5 NS
TPN 17 58 <0.05
PCA 52 56 NS
Mean LOS 21 22 NS
Median LOS 21 21 NS
Range for LOS 12-36 12-37 N/A
NS: Not statistically signiﬁcant (using P value of <0.05)answer this question. Important future studies should include
pharmacoeconomic analysis of the relationship between pal-
ifermin, TPN antibiotics, and growth factor use as well as
overall cost and outcomes of performing BEAM/ASCTwith and
without palifermin. A CIBMTR retrospective study with addi-
tional data collection analyzing palifermin use in BEAM auto-
patients may be an expeditious way to answer many of these
questions.309
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Background: Oral mucositis (OM) is a major complication of
HDM. Previous studies analyzing the role of oral cryotherapy
(CT) in the prevention of OM are small or include patients
treated with multiple conditioning regimens.
Study Purpose: To compare the efﬁcacy of CT plus saline
solution (SS) mouth rinse vs. SS alone vs. supersaturated
calcium phosphate rinses (Caphosol) to prevent HDM-
induced OM in patients with MM undergoing
autotransplantation
Methods: One hundred and seventeen MM patients,
scheduled to receive HDM (140-200 mg/m2) followed by
autotransplantation at the Audie L. Murphy Memorial Vet-
erans Hospital in San Antonio, Texas, were randomized to the
above mentioned groups (Table 1). Patients were assessed
daily for OM until discharge or resolution of OM, using the
World Health Organization (WHO) mucositis scale. Duration80 16 (14) 6 (15) 6 (15) 4 (11)
90 100 (85) 33 (85) 33 (82.5) 7 (89)
Serum
Creatinine,
mean (SD)
1.12
(0.67)
1.28
(0.93)
1.00
(0.29)
1.09
(0.63)
0.1715
Diabetes, n (%) 0.9912
Yes 30 (26) 10 (26) 10 (25) 10 (26)
No 87 (74) 29 (74) 30 (75) 28 (74)
Dentures, n (%) 0.6336
Yes 32 (27) 9 (23) 13 (32) 10 (26)
No 85 (73) 30 (77) 27 (68) 28 (74)
Smoking, n (%) 0.9122
Yes or
history
89 (76) 30 (77) 30 (75) 29 (76)
Never 28 (24) 9 (23) 10 (25) 9 (24)
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also evaluated.
Results: The study was stopped early due to the superiority
of CT. Ninety percent of patients in the CT group did not
experienced OM, compared to 36% and 34% in the Caphosolâ
and SS groups, respectively (P < 0.0001). None of the CT
patients experienced grade 3-4 OM. There was a signiﬁcant
decrement in duration of OM in the CT group compared to
the Caphosolâ group (mean duration [MD] in days 0.8 vs.
4.77; p < 0.001) and the SS group (MD 5.55 days; p < 0.001).
Duration of OMwas shorter in the CT group compared to the
SS group (MD .9 days vs. 3.38 days; p ¼ 0.004) and the
Caphosolâ group (MD 2.97 days; p¼ 0.020). Patients in the CT
group required less use of analgesics when compared with
the SS group (p ¼ 0.007).
Conclusion: CT signiﬁcantly reduces OM incidence, severity
and duration. . Patients who received CT had lower analgesic
requirements than patients who received SS.310
Amphotericin B Nasal Spray Appears Effective in
Preventing Breakthrough Fungal Infections in Colonized
SCT Recipients
Steven Triﬁlio 1, Ryan Heraty 1, Athanasios Zomas 1, Derek Liu 1,
Junyu Zhang 1, Cindy Zhao 1, Jayesh Mehta 2. 1 NorthwesternNumber of colonized patients(%) 109(5.6)
Total Isolates 117
Autologous 78(5.7)
Allogeneic (MDS) 14(5.4)
Allogeneic (MUD) 17(5)
Yeast (Non-speciated) 57
Alternaria 20
Penicillium 12
Aspergillus spp 11
Molds (Non-spp) 8
Cladosporium 3
Fusarium 2
Others 6
History of prior IFI 8
Change in systemic antifungal therapy 25
Eradication of nasal colonization(%) 100
Documented breakthrough IFI 1Memorial Hospital, Chicago, IL; 2 Hematology/Oncology,
Northwestern University Feinberg School of Medicine,
Chicago, IL
Fungal colonization may increase the risk for developing
invasive fungal infections(IFI) for patients undergoing stem
cell transplants (SCT). At Northwestern Memorial Hospital a
protocol was initiated in 2005 to administer amphotericin B
decanoate nasal spray to all SCT recipients with fungal nasal
colonization.
Amphotericin B 0.5% nasal spray was given twice daily in
addition to systemic prophylaxis (ﬂuconazole for auto-SCT’s
or voriconazole 200 mg for allo-SCT’s) to all patients with
nasal fungal colonization. Nasal surveillance cultures were
repeated within 7- 30 days of Ampho B initiation. An inde-
pendent expert reviewer was utilized to determine the
presence of IFI according to EORTC criteria.
Amongst1936patients reviewed,117 fungal isolates (62mould
and57yeast )were identiﬁed fromthenaresof109patients (78
auto/31allo). Therewasnosigniﬁcantdifference inage, gender,
diagnosis, transplant or donor type betweenpatientswith and
without nasal fungal colonization. Eight patients had a prior
history of IFI. Nasal surveillance cultures after Ampho B began
showed 100% eradication of all isolates. One breakthrough IFI
was observed amongst the 109 Ampho B treated patients
(Alternia ssp.soft tissue infection in auto-SCT successfully
treated with voriconazole). Systemic Antifungal prophylaxis
waschanged in25patients, primarily for febrileneutropeniaor
liver enzyme abnormalities. Nasal Ampho Bwaswell tolerated
and no patient discontinued use during transplantation.
Intranasal Ampho B effectively eradicates nasal fungal colo-
nization and appears effective in preventing breakthrough
fungal infections in colonized HSCT recipients.311
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